The LumenR tissue retractor system is currently being developed for use in endoscopic resection of lesions in the colon, esophagus or stomach.
It intends to enhance endoscopic sub-mucosal dissection (ESD) and endoscopic mucosal resection (EMR) procedures.
These procedures are less invasive alternatives to conventional surgery for the removal of precancerous lesions and malignant tumors in the gastrointestinal tract.
It will allow enhanced visualization of lesions and create a stable working environment to support tissue retraction and resection during ESD and EMR procedures, said the company.
LumenR will be included in the firm’s endoscopy development program to carry out additional development and evaluation of the system before commercialization.
ESD and EMR are frequently carried out under endoscopic treatments for colorectal, gastric and esophageal cancers.
Boston Scientific endoscopy president and senior vice president Art Butcher said: "We are excited about the potential of the LumenR system to improve visibility and control during ESD and EMR procedures and improve quality of life for patients.
"Every year, patients around the world undergo open gastrointestinal surgery that has a profound impact on their lives. By bringing this innovative technology forward, we have an opportunity for more physicians to treat patients successfully through less invasive endoscopic procedures."
LumenR founder and CEO Gregory Piskun said: "We have seen promising outcomes in reducing both procedure times and patient complications during our evaluation of the LumenR system.
In September, Boston Scientific agreed to acquire US medical technology firm EndoChoice for about $210m.
The company develops and produces platform technologies, including endoscopic imaging systems, devices and infection control products, as well as pathology services to treat different GI conditions.
Image: Boston Scientific's corporate headquarters in Marlborough, Massachusetts. Photo: courtesy of Boston Scientific Corporation.
